Jayasri G. Iyer

Jayasri G. Iyer

Auto-generated profile, based on publicly available information

Jayasri G. Iyer

University of Washington, Seattle, WA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2013 in Current Treatment Options in Oncology
Verified
Journal Article
Closed access
PDF file
NMNatalie J. Miller
Natalie J. Miller
SBShailender Bhatia
Shailender Bhatia
UPUpendra Parvathaneni
Upendra Parvathaneni
JIJayasri G. Iyer
Jayasri G. Iyer
PNPeter P. Nghiem
Peter P. Nghiem

20 May 2014 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SBShailender Bhatia
Shailender Bhatia
JIJayasri G Iyer
Jayasri G Iyer
BSBarry Storer
Barry Storer
AMAta Moshiri
Ata Moshiri
UPUpendra Parvathaneni
Upendra Parvathaneni
PNPeter P. Nghiem
Peter P. Nghiem
9014 Background: Merkel cell carcinoma (MCC) is an aggressive skin cancer with high risk of recurrence after surgery. Adjuvant radiation therapy (RT) and/or chemotherapy are commonly used, but with limited data regarding their effectiveness. To assess the impact of adjuvant RT and chemotherapy on MCC survival, we performed a retrospective analysis of the National Cancer Data Base (NCDB) that has the largest known cohort of MCC patients (pts). NCDB also collects data on adjuvant chemotherapy and comorbidity status (Charlson/Deyo score) that were missing in a prior study of outcomes with adjuvant RT in 1,487 pts in the Surveillance, Epidemiology, and End Results (SEER) database. Methods: 6,908 MCC pts with stage, treatment and survival data available were included in this analysis. Multiple covariate analyses were conducted for overall survival outcomes with various treatment modalities while adjusting for age, sex, comorbidity score, and other therapies. Results: In pts with localized MCC (AJCC stage I N=3,369; stage II N=1,474), surgery plus RT was associated with significantly better survival than seen with surgery alone (Stage I HR 0.75 [95% CI 0.67–0.83], p<0.0001; Stage II HR 0.77 [95% CI 0.67–0.90], p=0.0006). In pts with nodal involvement (stage III N=2,065), adjuvant chemotherapy was not associated with improved or worsened survival versus no chemotherapy (HR 1.07 [95% CI 0.93–1.22], p=0.37). Even among a subgroup of stage III pts aged < 65 and with comorbidity score=0, adjuvant chemotherapy was not associated with improved survival. Conclusions: This retrospective study analyzed the largest MCC dataset to date for outcomes with adjuvant therapy. These results suggest improved survival with the use of adjuvant RT in stage I-II MCC pts. Adjuvant RT or chemotherapy were not associated with improved survival in stage III MCC pts. Despite the ability to assess comorbidity scores, treatment biases that could have accounted for some of the observed effects cannot be directly addressed, and prospective multicenter evaluations of adjuvant RT and chemotherapy remain warranted. Until then, multidisciplinary evaluation and individualized care is appropriate for all pts with MCC.

1 January 2011
Verified
Book Chapter
Closed access
JIJayasri G. Iyer
Jayasri G. Iyer
RTRenee Thibodeau
Renee Thibodeau
PNPeter P. Nghiem
Peter P. Nghiem

1 January 2011
Verified
Book Chapter
Closed access
VAVerena Ahlgrimm-Siess
Verena Ahlgrimm-Siess
SASamuel Fehring Almquist
Samuel Fehring Almquist
SASadegh Amini
Sadegh Amini
RARobert H.I. Andtbacka
Robert H.I. Andtbacka
DADiana D. Antonovich
Diana D. Antonovich
BZBrittany A. Zwischenberger
Brittany A. Zwischenberger